Abstracts management in adult patients with refractory epilepsy in Spain. METHODS: A cross-sectional and retrospective study was designed. Male and female adult patients (above 18 years) with refractory epilepsy were enrolled in neurology medical settings between March and September 2005 in Spain. Health care and non-health care resources were collected and total costs calculated according with published prices for year 2005. Quality-oflife, level of anxiety and depression, health state, concomitant medications and comorbidity history and treatment of epilepsy were also recorded. A secondary analysis including a forward stepwise multivariate regression model exploring possible explicative variables was performed. RESULTS: Seven-hundredsixty-two consecutive patients [728 evaluables (95.5%); 50.8% males, 40.5 (13.5) years, 24.3 (13.4) years of evolution] were included through the country at epilepsy units, neurology outpatient clinics and hospital outpatient clinics. A moderate explicative model was built; adjusted R-square = 0.24 (F = 26.6, p < 0.0001). Presence of mental retardation and social function domain of the QOLIE-10 were the variables with most explicative weight of total cost in these patients; standardized estimates of 0.303 and 0.175, respectively [â coefficient (standard error) of 6675.0 (826.8) and 53.5 (12.7), p < 0.001 in both cases respectively]. Health status on a 0-100 mm-VAS (standardized estimate; 0.142), need for additional non-neurological hospital assistance (0.118), previous episode of secondarily generalized seizures (0.102), health care at neurology outpatient clinics (0.083), and documented etiology of epilepsy (0.096) were all found to be significant explicative variable, all of them p < 0.05. CONCLUSIONS: This secondary analysis found a broad sources of drivers of costs in patients with refractory epilepsy in Spain, with mental retardation and social function domain of QOLIE-10 (the higher the score the higher the cost) being responsible for a substantial part of total cost. Boehringer Ingelheim GmbH, Ingelheim, Germany OBJECTIVE: To estimate the cost-effectiveness of pramipexole versus no treatment in patients with moderate to very severe restless legs syndrome (RLS) in Sweden taking the societal perspective. METHODS: A cost-utility Markov model was developed that included five health states (no, mild, moderate, severe and very severe RLS) based on the International RLS Study Group Rating Scale scores. The probability of moving between health states was derived from the phase III, randomized, double-blind pramipexole trials in RLS. To comprehensively estimate qualityadjusted life years (QALYs) several approaches were taken to map the IRLS to the EQ-5D including Delphi panel, patient survey and published literature. Treatment patterns were estimated with a physician expert panel. 2005 unit costs were derived from Swedish government sources. Both one-way and probabilistic sensitivity analyses were conducted. RESULTS: Over a one-year time period, treatment with pramipexole reduced overall costs by SEK 1191 (approximately €128) per patient and was associated with a gain of 0.035 QALYs relative to no treatment when using utilities from the Delphi panel. Pramipexole's dominance from the societal perspective against the no treatment alternative was robust to sensitivity analysis. Sensitivity analyses included variation in health care provider costs, different utility assumptions, and an extension of the model to a five-year time period. CONCLUSIONS: Active treatment of RLS with pramipexole is preferred over no treatment for patients with moderate to very severe RLS in Sweden. A decision tree with a Bayesian approach and a Markov model were used. Mean cost-utility, incremental ratios and net health benefits were estimated. The sensitivity analysis included oneway, two-way, threshold and probabilistic with Monte Carlo simulation. RESULTS: Cost per utility unit for levodopacarbidopa was $5623 and for levodopa-carbidopa-entacapone, $5168. Incremental cost-utility ratio using levodopa-carbidopa as a comparator was $1585. Independently of WTP, levodopacarbidopa-entacapone had larger net health benefits than levodopa-carbidopa. In the five years analysis, levodopacarbidopa-entacapone showed 12.8% more utility in relationship to levodopa-carbidopa, with 3.5% more costs. The cost per utility unit with levodopa-carbidopa-entacapone had an accumulated decrease of 18.4% during the period of time analyzed. The acceptability curves and the component analysis of the ellipse graph showed that with the actual cost that the IMSS is investing in the treatment of Parkinson disease, the cost-utility proportion of levodopa-carbidopa-entacapone would be 80%. CONCLUSIONS: Levodopa-carbidopa-entacapone had the lowest cost per unit of success in the treatment of patients with Parkinson disease compared with levodopa-carbidopa. Cost per additional utility unit of levodopa-carbidopa-entacapone was $1585. At the end of the follow-up levodopa-carbidopa-entacapone reduced annual health care costs to a greater extent than levodopa-carbidopa and provided better quality of life per patient.
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COST-EFFECTIVENESS OF TREATING RESTLESS LEGS PATIENTS WITH PRAMIPEXOLE COMPARED TO NO TREATMENT IN SWEDEN
Lees
Boehringer Ingelheim GmbH, Ingelheim, Germany OBJECTIVE: To estimate the cost-effectiveness of pramipexole versus no treatment in patients with moderate to very severe restless legs syndrome (RLS) in Sweden taking the societal perspective. METHODS: A cost-utility Markov model was developed that included five health states (no, mild, moderate, severe and very severe RLS) based on the International RLS Study Group Rating Scale scores. The probability of moving between health states was derived from the phase III, randomized, double-blind pramipexole trials in RLS. To comprehensively estimate qualityadjusted life years (QALYs) several approaches were taken to map the IRLS to the EQ-5D including Delphi panel, patient survey and published literature. Treatment patterns were estimated with a physician expert panel. 2005 unit costs were derived from Swedish government sources. Both one-way and probabilistic sensitivity analyses were conducted. RESULTS: Over a one-year time period, treatment with pramipexole reduced overall costs by SEK 1191 (approximately €128) per patient and was associated with a gain of 0.035 QALYs relative to no treatment when using utilities from the Delphi panel. Pramipexole's dominance from the societal perspective against the no treatment alternative was robust to sensitivity analysis. Sensitivity analyses included variation in health care provider costs, different utility assumptions, and an extension of the model to a five-year time period. CONCLUSIONS: Active treatment of RLS with pramipexole is preferred over no treatment for patients with moderate to very severe RLS in Sweden. A decision tree with a Bayesian approach and a Markov model were used. Mean cost-utility, incremental ratios and net health benefits were estimated. The sensitivity analysis included oneway, two-way, threshold and probabilistic with Monte Carlo simulation. RESULTS: Cost per utility unit for levodopacarbidopa was $5623 and for levodopa-carbidopa-entacapone, $5168. Incremental cost-utility ratio using levodopa-carbidopa as a comparator was $1585. Independently of WTP, levodopacarbidopa-entacapone had larger net health benefits than levodopa-carbidopa. In the five years analysis, levodopacarbidopa-entacapone showed 12.8% more utility in relationship to levodopa-carbidopa, with 3.5% more costs. The cost per utility unit with levodopa-carbidopa-entacapone had an accumulated decrease of 18.4% during the period of time analyzed. The acceptability curves and the component analysis of the ellipse graph showed that with the actual cost that the IMSS is investing in the treatment of Parkinson disease, the cost-utility proportion of levodopa-carbidopa-entacapone would be 80%. CONCLUSIONS: Levodopa-carbidopa-entacapone had the lowest cost per unit of success in the treatment of patients with Parkinson disease compared with levodopa-carbidopa. Cost per additional utility unit of levodopa-carbidopa-entacapone was $1585. At the end of the follow-up levodopa-carbidopa-entacapone reduced annual health care costs to a greater extent than levodopa-carbidopa and provided better quality of life per patient.
PND10 A FUNCTIONAL ANALYSIS OF THE RELATIONSHIP BETWEEN AGE AND MIGRAINE IN THE UNITED STATES OF AMERICA
Victor TW, Barlas S Endo Pharmaceuticals, Chadds Ford, PA, USA OBJECTIVE: The objective of this study was to evaluate the indirect evidence of menstrual migraine headache by examining migraine headache prevalence as a function of age. Investigators have reported that the risk of migraine headache decreases with age but have not fully described the nature of the decline based on sex. METHODS: This study was based on data from the adult sample of the 2003 National Health Interview Survey (NHIS). The study sample consisted of 17,394 females and 13,396 males representing 212.7 million American adults aged 18 to 85+ years. Nonparametric regression models were employed to express migraine prevalence as a function of age separately for each sex group. The salient characteristics of the fitted functions were evaluated by examining the first and second derivatives, corresponding to the velocity and the acceleration of prevalence over the age continuum. RESULTS: Study results suggest that migraine prevalence increases with age until about 34 years, where it reaches a maximum, then starts declining until 75 years where it reaches a plateau for both sexes. For females, the greatest rate of decline in migraine prevalence starts at 41 years and continues until age 63 where it reaches its minimum. The rate of decline in migraine prevalence for males, on the other hand, seems to be decreasing in a smooth monotonic fashion starting age 34 and reaches the female rate of change at 78 years. The dramatic change in both the slope and the curvature of the function for females around the perimenopausal age range warrants attention. CONCLUSIONS: These findings provide indirect evidence for the phenomenon of menstrual migraine. The inflection points on the female curve correspond to the age range of perimenopause and menopause in U.S. women. These inflection points are not observed on the male curve.
PND11 MODELING LONG-TERM "REAL WORLD" OUTCOMES OF DISEASE-MODIFYING THERAPY IN RELAPSING-REMITTING ONSET MULTIPLE SCLEROSIS
Dalhousie University, Halifax, NS, Canada, 2 Capital Health Nova Scotia, Halifax, NS, Canada OBJECTIVES: Phase III clinical trials showed novel drugs introduced in the 1990s modified the natural history (NH) of relapsing-remitting onset definite multiple sclerosis (MS). A Nova Scotia Phase IV "real world" observational study confirmed the short-term effectiveness of these disease modifying therapies (MS-DMT), measured by Extended Disability Status Scale (EDSS) increase avoided per patient per year. This analysis projects these short-term results over a 20-year horizon to estimate long-term health outcomes of MS-DMT. METHODS: A probabilistic Markov model estimated EDSS progression for NH and MS-DMT cohorts with relapsing-remitting onset MS over a 20-year horizon. The model was based on 591 patients receiving MS-DMT from the Dalhousie MS Research Unit, stratified into three subgroups by final classification and disability severity: 1) mild relapsing-remitting MS (RRMS), 2) mild secondary-progressive MS (SPMS) and 3) mild or moderate SPMS. Health outcomes were measured as EDSS disability adjusted life years (DALYs) avoided per patient compared to NH. Relative benefit was defined as DALY burden avoided relative to expected DALYs given NH. The baseline analysis was a "best-case" scenario with full compliance for 20 years. RESULTS: The model found statistically significant benefit in all three subgroups. Among the mild severity subgroups, there were 1.7 (95% CI:1.2-2.2) DALYs avoided among RRMS patients and 2.6 (1.5-3.6) DALYs avoided among SPMS patients, for a combined benefit of 1.9 (1.2-3.2) DALYs avoided, or a 42% (20%-91%) relative benefit. Among the mild or moderate SPMS patients there were 1.1 (0.3-1.9) DALYs avoided (14%; 3-30%). Overall, the combined cohort had a benefit of 1.5 (0.5-2.1) DALYs avoided (29%; 6-63%). CONCLUSIONS: MS-DMT can have significant long-term benefit in terms of DALYs avoided, particularly in mild subgroups. This analysis is the first to model long-term change in mean EDSS, rather than delayed time to specific EDSS endpoints, and may help guide MS-DMT coverage decisions.
